« Return to News | Drug Sponsors

Tengion CEO Nichtberger resigns

Friday, July 1, 2011 10:02 AM

Dr. Steven A. Nichtberger has resigned as president and CEO of Tengion, a regenerative medicine company focused on developing replacement organs and tissues grown from a person’s own cells, according to a report in the Philadelphia Business Journal.

Nichtberger is also stepping down from the company’s board of directors.

“I am pleased that as I leave my role at Tengion, the company is positioned to pursue the advancement of its organ regeneration platform and I wish Tengion success in bringing its product candidates to patients in need,” said Nichtberger in a statement released by the company.

Tengion of East Norriton, Pa., said David I. Scheer, the company’s board chairman, will assume a more active role in guiding the company while an external search is conducted for a new chief executive officer.

Nichtberger was at the helm at Tengion earlier this year when the company’s dwindling cash flow problem was resolved through a $31.4 million private stock sale.

Tengion reaffirmed its plan to submit next quarter to the FDA additional clinical data and modifications to the surgical approach for its experimental Neo-Urinary Conduit product.

The company also reiterated its plans to request a meeting with the FDA by the end of this year to discuss its plan for conducting clinical trials for its Neo-Kidney Augment product, which is intended to prevent or delay the need for dialysis or kidney transplant by increasing functional kidney mass in patients with advanced chronic kidney disease.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.